Review



imscs  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    ATCC imscs
    Imscs, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 70 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/imscs/product/ATCC
    Average 95 stars, based on 70 article reviews
    imscs - by Bioz Stars, 2026-03
    95/100 stars

    Images



    Similar Products

    imscs  (ATCC)
    95
    ATCC imscs
    Imscs, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/imscs/product/ATCC
    Average 95 stars, based on 1 article reviews
    imscs - by Bioz Stars, 2026-03
    95/100 stars
      Buy from Supplier

    95
    ATCC mscs imscs
    Substrate and BM‐MSC EV characterization. (a) Elastic moduli of substrates made with varying ratios of Sylgard 184 base to crosslinker reagents. All values expressed as mean ± SD ( n = 3). (b) Absorbance values indicating cell viability as determined by CCK8 assay over 5 days. All values expressed as mean ± SD ( n = 3). (c) Size distribution from nanoparticle tracking analysis of EVs isolated from <t>BM‐MSCs</t> seeded on Sylgard 184 PDMS substrates with differing base to crosslinker reagent ratios ( n = 3). (d) Representative Western blot of BM‐MSC EVs from each of the Sylgard 184 PDMS substrates and the corresponding cell lysates for EV‐positive markers ALIX, TSG101, and CD63 and cellular markers Calnexin and GAPDH (15 μg/lane). (e) Representative TEM images of BM‐MSC EVs from the softest Sylgard 184 PDMS substrates and collagen‐coated flasks. Statistical significance was determined by ANOVA; **p < 0.01, ***p < 0.001, and ****p < 0.0001.
    Mscs Imscs, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mscs imscs/product/ATCC
    Average 95 stars, based on 1 article reviews
    mscs imscs - by Bioz Stars, 2026-03
    95/100 stars
      Buy from Supplier

    90
    FUJIFILM imscs msc-301-010-001-pt
    Substrate and BM‐MSC EV characterization. (a) Elastic moduli of substrates made with varying ratios of Sylgard 184 base to crosslinker reagents. All values expressed as mean ± SD ( n = 3). (b) Absorbance values indicating cell viability as determined by CCK8 assay over 5 days. All values expressed as mean ± SD ( n = 3). (c) Size distribution from nanoparticle tracking analysis of EVs isolated from <t>BM‐MSCs</t> seeded on Sylgard 184 PDMS substrates with differing base to crosslinker reagent ratios ( n = 3). (d) Representative Western blot of BM‐MSC EVs from each of the Sylgard 184 PDMS substrates and the corresponding cell lysates for EV‐positive markers ALIX, TSG101, and CD63 and cellular markers Calnexin and GAPDH (15 μg/lane). (e) Representative TEM images of BM‐MSC EVs from the softest Sylgard 184 PDMS substrates and collagen‐coated flasks. Statistical significance was determined by ANOVA; **p < 0.01, ***p < 0.001, and ****p < 0.0001.
    Imscs Msc 301 010 001 Pt, supplied by FUJIFILM, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/imscs msc-301-010-001-pt/product/FUJIFILM
    Average 90 stars, based on 1 article reviews
    imscs msc-301-010-001-pt - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    Cynata Therapeutics clinical-grade imsc product cyp001 tm
    Substrate and BM‐MSC EV characterization. (a) Elastic moduli of substrates made with varying ratios of Sylgard 184 base to crosslinker reagents. All values expressed as mean ± SD ( n = 3). (b) Absorbance values indicating cell viability as determined by CCK8 assay over 5 days. All values expressed as mean ± SD ( n = 3). (c) Size distribution from nanoparticle tracking analysis of EVs isolated from <t>BM‐MSCs</t> seeded on Sylgard 184 PDMS substrates with differing base to crosslinker reagent ratios ( n = 3). (d) Representative Western blot of BM‐MSC EVs from each of the Sylgard 184 PDMS substrates and the corresponding cell lysates for EV‐positive markers ALIX, TSG101, and CD63 and cellular markers Calnexin and GAPDH (15 μg/lane). (e) Representative TEM images of BM‐MSC EVs from the softest Sylgard 184 PDMS substrates and collagen‐coated flasks. Statistical significance was determined by ANOVA; **p < 0.01, ***p < 0.001, and ****p < 0.0001.
    Clinical Grade Imsc Product Cyp001 Tm, supplied by Cynata Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/clinical-grade imsc product cyp001 tm/product/Cynata Therapeutics
    Average 90 stars, based on 1 article reviews
    clinical-grade imsc product cyp001 tm - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    iCell Gene Therapeutics commercial-grade imscs icell mesenchymal stemcellstm
    Substrate and BM‐MSC EV characterization. (a) Elastic moduli of substrates made with varying ratios of Sylgard 184 base to crosslinker reagents. All values expressed as mean ± SD ( n = 3). (b) Absorbance values indicating cell viability as determined by CCK8 assay over 5 days. All values expressed as mean ± SD ( n = 3). (c) Size distribution from nanoparticle tracking analysis of EVs isolated from <t>BM‐MSCs</t> seeded on Sylgard 184 PDMS substrates with differing base to crosslinker reagent ratios ( n = 3). (d) Representative Western blot of BM‐MSC EVs from each of the Sylgard 184 PDMS substrates and the corresponding cell lysates for EV‐positive markers ALIX, TSG101, and CD63 and cellular markers Calnexin and GAPDH (15 μg/lane). (e) Representative TEM images of BM‐MSC EVs from the softest Sylgard 184 PDMS substrates and collagen‐coated flasks. Statistical significance was determined by ANOVA; **p < 0.01, ***p < 0.001, and ****p < 0.0001.
    Commercial Grade Imscs Icell Mesenchymal Stemcellstm, supplied by iCell Gene Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/commercial-grade imscs icell mesenchymal stemcellstm/product/iCell Gene Therapeutics
    Average 90 stars, based on 1 article reviews
    commercial-grade imscs icell mesenchymal stemcellstm - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    Cynata Therapeutics cyp001tm clinical imscs 1-3
    Substrate and BM‐MSC EV characterization. (a) Elastic moduli of substrates made with varying ratios of Sylgard 184 base to crosslinker reagents. All values expressed as mean ± SD ( n = 3). (b) Absorbance values indicating cell viability as determined by CCK8 assay over 5 days. All values expressed as mean ± SD ( n = 3). (c) Size distribution from nanoparticle tracking analysis of EVs isolated from <t>BM‐MSCs</t> seeded on Sylgard 184 PDMS substrates with differing base to crosslinker reagent ratios ( n = 3). (d) Representative Western blot of BM‐MSC EVs from each of the Sylgard 184 PDMS substrates and the corresponding cell lysates for EV‐positive markers ALIX, TSG101, and CD63 and cellular markers Calnexin and GAPDH (15 μg/lane). (e) Representative TEM images of BM‐MSC EVs from the softest Sylgard 184 PDMS substrates and collagen‐coated flasks. Statistical significance was determined by ANOVA; **p < 0.01, ***p < 0.001, and ****p < 0.0001.
    Cyp001tm Clinical Imscs 1 3, supplied by Cynata Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cyp001tm clinical imscs 1-3/product/Cynata Therapeutics
    Average 90 stars, based on 1 article reviews
    cyp001tm clinical imscs 1-3 - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    Cynata Therapeutics clinical-grade imsc product cyp001tm
    Substrate and BM‐MSC EV characterization. (a) Elastic moduli of substrates made with varying ratios of Sylgard 184 base to crosslinker reagents. All values expressed as mean ± SD ( n = 3). (b) Absorbance values indicating cell viability as determined by CCK8 assay over 5 days. All values expressed as mean ± SD ( n = 3). (c) Size distribution from nanoparticle tracking analysis of EVs isolated from <t>BM‐MSCs</t> seeded on Sylgard 184 PDMS substrates with differing base to crosslinker reagent ratios ( n = 3). (d) Representative Western blot of BM‐MSC EVs from each of the Sylgard 184 PDMS substrates and the corresponding cell lysates for EV‐positive markers ALIX, TSG101, and CD63 and cellular markers Calnexin and GAPDH (15 μg/lane). (e) Representative TEM images of BM‐MSC EVs from the softest Sylgard 184 PDMS substrates and collagen‐coated flasks. Statistical significance was determined by ANOVA; **p < 0.01, ***p < 0.001, and ****p < 0.0001.
    Clinical Grade Imsc Product Cyp001tm, supplied by Cynata Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/clinical-grade imsc product cyp001tm/product/Cynata Therapeutics
    Average 90 stars, based on 1 article reviews
    clinical-grade imsc product cyp001tm - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    Cynata Therapeutics clinical imsc product cyp001
    Substrate and BM‐MSC EV characterization. (a) Elastic moduli of substrates made with varying ratios of Sylgard 184 base to crosslinker reagents. All values expressed as mean ± SD ( n = 3). (b) Absorbance values indicating cell viability as determined by CCK8 assay over 5 days. All values expressed as mean ± SD ( n = 3). (c) Size distribution from nanoparticle tracking analysis of EVs isolated from <t>BM‐MSCs</t> seeded on Sylgard 184 PDMS substrates with differing base to crosslinker reagent ratios ( n = 3). (d) Representative Western blot of BM‐MSC EVs from each of the Sylgard 184 PDMS substrates and the corresponding cell lysates for EV‐positive markers ALIX, TSG101, and CD63 and cellular markers Calnexin and GAPDH (15 μg/lane). (e) Representative TEM images of BM‐MSC EVs from the softest Sylgard 184 PDMS substrates and collagen‐coated flasks. Statistical significance was determined by ANOVA; **p < 0.01, ***p < 0.001, and ****p < 0.0001.
    Clinical Imsc Product Cyp001, supplied by Cynata Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/clinical imsc product cyp001/product/Cynata Therapeutics
    Average 90 stars, based on 1 article reviews
    clinical imsc product cyp001 - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    Dawley Inc imsc-sev
    Substrate and BM‐MSC EV characterization. (a) Elastic moduli of substrates made with varying ratios of Sylgard 184 base to crosslinker reagents. All values expressed as mean ± SD ( n = 3). (b) Absorbance values indicating cell viability as determined by CCK8 assay over 5 days. All values expressed as mean ± SD ( n = 3). (c) Size distribution from nanoparticle tracking analysis of EVs isolated from <t>BM‐MSCs</t> seeded on Sylgard 184 PDMS substrates with differing base to crosslinker reagent ratios ( n = 3). (d) Representative Western blot of BM‐MSC EVs from each of the Sylgard 184 PDMS substrates and the corresponding cell lysates for EV‐positive markers ALIX, TSG101, and CD63 and cellular markers Calnexin and GAPDH (15 μg/lane). (e) Representative TEM images of BM‐MSC EVs from the softest Sylgard 184 PDMS substrates and collagen‐coated flasks. Statistical significance was determined by ANOVA; **p < 0.01, ***p < 0.001, and ****p < 0.0001.
    Imsc Sev, supplied by Dawley Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/imsc-sev/product/Dawley Inc
    Average 90 stars, based on 1 article reviews
    imsc-sev - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    Image Search Results


    Substrate and BM‐MSC EV characterization. (a) Elastic moduli of substrates made with varying ratios of Sylgard 184 base to crosslinker reagents. All values expressed as mean ± SD ( n = 3). (b) Absorbance values indicating cell viability as determined by CCK8 assay over 5 days. All values expressed as mean ± SD ( n = 3). (c) Size distribution from nanoparticle tracking analysis of EVs isolated from BM‐MSCs seeded on Sylgard 184 PDMS substrates with differing base to crosslinker reagent ratios ( n = 3). (d) Representative Western blot of BM‐MSC EVs from each of the Sylgard 184 PDMS substrates and the corresponding cell lysates for EV‐positive markers ALIX, TSG101, and CD63 and cellular markers Calnexin and GAPDH (15 μg/lane). (e) Representative TEM images of BM‐MSC EVs from the softest Sylgard 184 PDMS substrates and collagen‐coated flasks. Statistical significance was determined by ANOVA; **p < 0.01, ***p < 0.001, and ****p < 0.0001.

    Journal: Bioengineering & Translational Medicine

    Article Title: Mesenchymal stem cell extracellular vesicle vascularization bioactivity and production yield are responsive to cell culture substrate stiffness

    doi: 10.1002/btm2.10743

    Figure Lengend Snippet: Substrate and BM‐MSC EV characterization. (a) Elastic moduli of substrates made with varying ratios of Sylgard 184 base to crosslinker reagents. All values expressed as mean ± SD ( n = 3). (b) Absorbance values indicating cell viability as determined by CCK8 assay over 5 days. All values expressed as mean ± SD ( n = 3). (c) Size distribution from nanoparticle tracking analysis of EVs isolated from BM‐MSCs seeded on Sylgard 184 PDMS substrates with differing base to crosslinker reagent ratios ( n = 3). (d) Representative Western blot of BM‐MSC EVs from each of the Sylgard 184 PDMS substrates and the corresponding cell lysates for EV‐positive markers ALIX, TSG101, and CD63 and cellular markers Calnexin and GAPDH (15 μg/lane). (e) Representative TEM images of BM‐MSC EVs from the softest Sylgard 184 PDMS substrates and collagen‐coated flasks. Statistical significance was determined by ANOVA; **p < 0.01, ***p < 0.001, and ****p < 0.0001.

    Article Snippet: Human induced pluripotent stem cell‐derived MSCs (iMSCs) were also purchased from ATCC (ACS‐7010).

    Techniques: CCK-8 Assay, Isolation, Western Blot

    Substrate stiffness influences BM‐MSC EV production and bioactivity. (a) EV production as quantified by EVs per cell from BM‐MSCs seeded on Sylgard 184 PDMS substrates with different base‐to‐crosslinker ratios. EVs used for this data were from 1 day of collection and isolated and counted separately from the conditioned media from the other 2 days. After media collection, cells were trypsinized and counted ( n = 3). (b) After a scratch was induced, HUVECs were treated with BM‐MSC EVs from the different substrates or growth or basal media, and percent gap closure after 20 h was evaluated via microscopy ( n = 3). (c) HUVECs were resuspended in EV treatments or growth or basal endothelial media, seeded in Matrigel‐coated wells, and tube formation after 3–6 h was quantified by the number of loops that had formed ( n = 3). All values expressed as mean ± SD. All data are representative of at least three independent experiments ( n = 3). Statistical significance was determined by ANOVA; *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.

    Journal: Bioengineering & Translational Medicine

    Article Title: Mesenchymal stem cell extracellular vesicle vascularization bioactivity and production yield are responsive to cell culture substrate stiffness

    doi: 10.1002/btm2.10743

    Figure Lengend Snippet: Substrate stiffness influences BM‐MSC EV production and bioactivity. (a) EV production as quantified by EVs per cell from BM‐MSCs seeded on Sylgard 184 PDMS substrates with different base‐to‐crosslinker ratios. EVs used for this data were from 1 day of collection and isolated and counted separately from the conditioned media from the other 2 days. After media collection, cells were trypsinized and counted ( n = 3). (b) After a scratch was induced, HUVECs were treated with BM‐MSC EVs from the different substrates or growth or basal media, and percent gap closure after 20 h was evaluated via microscopy ( n = 3). (c) HUVECs were resuspended in EV treatments or growth or basal endothelial media, seeded in Matrigel‐coated wells, and tube formation after 3–6 h was quantified by the number of loops that had formed ( n = 3). All values expressed as mean ± SD. All data are representative of at least three independent experiments ( n = 3). Statistical significance was determined by ANOVA; *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.

    Article Snippet: Human induced pluripotent stem cell‐derived MSCs (iMSCs) were also purchased from ATCC (ACS‐7010).

    Techniques: Isolation, Microscopy

    Softer 184:527 PDMS substrates improve the angiogenic bioactivity of BM‐MSC EVs. (a) EV production quantified as EV per cell from BM‐MSCs seeded on each substrate made with different ratios of Sylgard 184 and Sylgard 527 ( n = 2). EVs used for this data were from 1 day of collection and isolated and counted separately from the conditioned media from the other 2 days. After media collection, cells were trypsinized and counted. (b) After a scratch was induced, HUVECs were treated with BM‐MSC EVs from the different substrates or growth or basal media, and percent gap closure after 20 h was evaluated via microscopy ( n = 3). (c) HUVECs were resuspended in the different EV treatments or growth or basal endothelial basal media, and tube formation after 3–6 h was quantified by the number of loops that had formed ( n = 3). All values expressed as mean ± SD. Statistical significance was determined by ANOVA; * p < 0.05, ** p < 0.01, and **** p < 0.0001.

    Journal: Bioengineering & Translational Medicine

    Article Title: Mesenchymal stem cell extracellular vesicle vascularization bioactivity and production yield are responsive to cell culture substrate stiffness

    doi: 10.1002/btm2.10743

    Figure Lengend Snippet: Softer 184:527 PDMS substrates improve the angiogenic bioactivity of BM‐MSC EVs. (a) EV production quantified as EV per cell from BM‐MSCs seeded on each substrate made with different ratios of Sylgard 184 and Sylgard 527 ( n = 2). EVs used for this data were from 1 day of collection and isolated and counted separately from the conditioned media from the other 2 days. After media collection, cells were trypsinized and counted. (b) After a scratch was induced, HUVECs were treated with BM‐MSC EVs from the different substrates or growth or basal media, and percent gap closure after 20 h was evaluated via microscopy ( n = 3). (c) HUVECs were resuspended in the different EV treatments or growth or basal endothelial basal media, and tube formation after 3–6 h was quantified by the number of loops that had formed ( n = 3). All values expressed as mean ± SD. Statistical significance was determined by ANOVA; * p < 0.05, ** p < 0.01, and **** p < 0.0001.

    Article Snippet: Human induced pluripotent stem cell‐derived MSCs (iMSCs) were also purchased from ATCC (ACS‐7010).

    Techniques: Isolation, Microscopy

    (a) EV production as quantified by EV per cell by EVs from iMSCs on different PDMS substrates. (b) EV size and concentration distribution from iMSCs cultured on different PDMS substrates as determined by nanoparticle tracking analysis. (c) iMSC proliferation/viability on PDMS substrates as measured by cell counting over 4 days. (d) Representative TEM images of F + C EVs and 527 EVs confirming morphology. (e) Western blot of EV markers CD63, ALIX, and TSG101, and EV‐negative marker, calnexin, on EVs from each PDMS substrate (12 μg/lane). (f) Western blot of MSC markers CD73, CD105, and CD90 and negative marker CD45 on iMSC lysate from each PDMS substrate. THP1 cell lysate was used as a positive control for CD45. (5 μg/lane). All values expressed as mean ± SD. Statistical significance was determined by ANOVA; ** p < 0.01.

    Journal: Bioengineering & Translational Medicine

    Article Title: Mesenchymal stem cell extracellular vesicle vascularization bioactivity and production yield are responsive to cell culture substrate stiffness

    doi: 10.1002/btm2.10743

    Figure Lengend Snippet: (a) EV production as quantified by EV per cell by EVs from iMSCs on different PDMS substrates. (b) EV size and concentration distribution from iMSCs cultured on different PDMS substrates as determined by nanoparticle tracking analysis. (c) iMSC proliferation/viability on PDMS substrates as measured by cell counting over 4 days. (d) Representative TEM images of F + C EVs and 527 EVs confirming morphology. (e) Western blot of EV markers CD63, ALIX, and TSG101, and EV‐negative marker, calnexin, on EVs from each PDMS substrate (12 μg/lane). (f) Western blot of MSC markers CD73, CD105, and CD90 and negative marker CD45 on iMSC lysate from each PDMS substrate. THP1 cell lysate was used as a positive control for CD45. (5 μg/lane). All values expressed as mean ± SD. Statistical significance was determined by ANOVA; ** p < 0.01.

    Article Snippet: Human induced pluripotent stem cell‐derived MSCs (iMSCs) were also purchased from ATCC (ACS‐7010).

    Techniques: Concentration Assay, Cell Culture, Cell Counting, Western Blot, Marker, Positive Control

    Substrate stiffness affects the pro‐angiogenic effect of iMSC EVs comparably to BM‐MSC EVs. (a) EVs isolated from iMSCs on different 184:527 PDMS substrates were used to treat HUVECs after a scratch had been induced, and percent gap closure after 20 h was evaluated via microscopy. (b) HUVECs were resuspended with the same EV groups and seeded, and tube formation after 3–6 h was quantified by the number of loops that had formed. All values expressed as mean ± SD. All data are representative of at least three independent experiments ( n = 3). Statistical significance was determined by ANOVA; * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001.

    Journal: Bioengineering & Translational Medicine

    Article Title: Mesenchymal stem cell extracellular vesicle vascularization bioactivity and production yield are responsive to cell culture substrate stiffness

    doi: 10.1002/btm2.10743

    Figure Lengend Snippet: Substrate stiffness affects the pro‐angiogenic effect of iMSC EVs comparably to BM‐MSC EVs. (a) EVs isolated from iMSCs on different 184:527 PDMS substrates were used to treat HUVECs after a scratch had been induced, and percent gap closure after 20 h was evaluated via microscopy. (b) HUVECs were resuspended with the same EV groups and seeded, and tube formation after 3–6 h was quantified by the number of loops that had formed. All values expressed as mean ± SD. All data are representative of at least three independent experiments ( n = 3). Statistical significance was determined by ANOVA; * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001.

    Article Snippet: Human induced pluripotent stem cell‐derived MSCs (iMSCs) were also purchased from ATCC (ACS‐7010).

    Techniques: Isolation, Microscopy

    MiRNA qPCR array data of differentially expressed MSC EV‐associated miRNAs in flask vs. soft substrate‐generated EVs. (a) Fold change of miRNAs within EVs from iMSCs seeded on 527 PDMS normalized to the miRNA levels within EVs from iMSCs seeded on collagen‐coated flasks. (b) The same data represented as the log2 of the fold change, again normalized to the miRNA levels within EVs from iMSCs seeded on collagen‐coated flasks. All data are representative of at least three independent experiments ( n = 3).

    Journal: Bioengineering & Translational Medicine

    Article Title: Mesenchymal stem cell extracellular vesicle vascularization bioactivity and production yield are responsive to cell culture substrate stiffness

    doi: 10.1002/btm2.10743

    Figure Lengend Snippet: MiRNA qPCR array data of differentially expressed MSC EV‐associated miRNAs in flask vs. soft substrate‐generated EVs. (a) Fold change of miRNAs within EVs from iMSCs seeded on 527 PDMS normalized to the miRNA levels within EVs from iMSCs seeded on collagen‐coated flasks. (b) The same data represented as the log2 of the fold change, again normalized to the miRNA levels within EVs from iMSCs seeded on collagen‐coated flasks. All data are representative of at least three independent experiments ( n = 3).

    Article Snippet: Human induced pluripotent stem cell‐derived MSCs (iMSCs) were also purchased from ATCC (ACS‐7010).

    Techniques: Generated